RTW Fund Group GP, LLC - 29 Jul 2026 Form 4 Insider Report for Yarrow Bioscience, Inc. (VYNE)

Reporting relationship: 10%+ Owner
Issuer ticker: VYNE
Reported as of: 29 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2026, 16:05:03 UTC
Prior SEC filing: 30 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Roderick Wong, for RTW Fund Group GP, LLC By: Roderick Wong, M.D., Managing Member

Key filing fact

RTW Fund Group GP, LLC filed Form 4 for Yarrow Bioscience, Inc. (VYNE) on 30 Jul 2026.

Key facts

This page summarizes RTW Fund Group GP, LLC's Form 4 filing for Yarrow Bioscience, Inc. (VYNE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Jul 2026, 16:05.

Change

Previous filing in this sequence was filed on 30 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002147397 Primary reporting owner

RTW Fund Group GP, LLC

Relationship: 10%+ Owner
Address: 40 10TH AVENUE, FLOOR 7, NEW YORK
Signature: /s/ Roderick Wong, for RTW Fund Group GP, LLC By: Roderick Wong, M.D., Managing Member
Signature date: 30 Jul 2026

CIK 0001493280

WONG RODERICK

Relationship: 10%+ Owner
Address: 40 10TH AVENUE, FLOOR 7, NEW YORK
Signature: /s/ Roderick Wong By: Roderick Wong, M.D.
Signature date: 30 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNE transaction

Common Stock

Other

Transaction value
Shares: -133,290
Change %: -33%
Price: $0.000000^*
Shares after: 266,307
Date: 29 Jul 2026
Ownership: See footnote
Footnotes: F1, F2

VYNE transaction

Common Stock

Other

Transaction value
Shares: -133,290
Change %: -33%
Price: $0.000000^*
Shares after: 266,307
Date: 29 Jul 2026
Ownership: See footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE transaction Derivative

Pre-Funded Warrants (Right to Buy)

Other

Transaction value
Shares: +133,290
Change %: +1.5%
Price: $0.000000^*
Shares after: 8,949,719
Date: 29 Jul 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 133,290
Exercise price: $0.000100
Footnotes: F1, F2, F3

VYNE transaction Derivative

Pre-Funded Warrants (Right to Buy)

Other

Transaction value
Shares: +133,290
Change %: +1.5%
Price: $0.000000^*
Shares after: 8,949,719
Date: 29 Jul 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 133,290
Exercise price: $0.000100
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

RTW Fund Group GP, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the terms of that certain Exchange Agreement, dated as of July 29, 2026, RTW Entity (as defined below) exchanged 133,290 shares of the Issuer's common stock for pre-funded warrants to purchase an equivalent number of shares of the Issuer's common stock.

Footnote F2

Held by a certain affiliated entity ("RTW Entity") managed by RTW Fund Group GP, LLC ("RTW Fund Group"). Roderick Wong, M.D. serves as the Managing Member of RTW Fund Group. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.

Footnote F3

The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.